Manufacturer
ACCORD HEALTHCARE SDN.BHD.
Contents
Docetaxel
Indication
Monotherapy for locally advanced or metastatic breast cancer; recurrent &/or metastatic squamous cell head & neck carcinoma after failure of previous chemotherapy regimen. In combination w/ doxorubicin for locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy. In combination w/ capecitabine for locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Locally advanced or metastatic non-small cell lung cancer after failure of platinum-based chemotherapy. In combination w/ cisplatin for unresectable, locally advanced or metastatic non-small cell lung cancer in patients who have not previously received chemotherapy. In combination w/ prednisone or prednisolone for hormone refractory metastatic prostatic cancer. In combination w/ cisplatin & 5-fluorouracil for metastatic gastric adenocarcinoma who have not received prior chemotherapy & locally advanced squamous cell head & neck carcinoma.
Drug interaction
Modified metabolism by CYP450 3A4 inducers/inhibitors eg, ciclosporine, ketoconazole, erythromycin. Increased carboplatin clearance.
ACCORD HEALTHCARE SDN.BHD.
Contents
Docetaxel
Indication
Monotherapy for locally advanced or metastatic breast cancer; recurrent &/or metastatic squamous cell head & neck carcinoma after failure of previous chemotherapy regimen. In combination w/ doxorubicin for locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy. In combination w/ capecitabine for locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Locally advanced or metastatic non-small cell lung cancer after failure of platinum-based chemotherapy. In combination w/ cisplatin for unresectable, locally advanced or metastatic non-small cell lung cancer in patients who have not previously received chemotherapy. In combination w/ prednisone or prednisolone for hormone refractory metastatic prostatic cancer. In combination w/ cisplatin & 5-fluorouracil for metastatic gastric adenocarcinoma who have not received prior chemotherapy & locally advanced squamous cell head & neck carcinoma.
Drug interaction
Modified metabolism by CYP450 3A4 inducers/inhibitors eg, ciclosporine, ketoconazole, erythromycin. Increased carboplatin clearance.
Inquiry - Taxtas 20mg/1ml concentrate Solution for Infusion